With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

As a result, the positive rate of amyloid beta protein, which shows the risk of amyloid accumulation, a causative agent of ...

This increase correlated with changes in biomarkers associated with neurodegenerative diseases like Alzheimer’s, such as ...

We now find ourselves at a point where commercially available plasma biomarker tests are demonstrating an extremely high ...

Leqembi’s sales continue to be underwhelming, according to analysts, who contend the companies’ Alzheimer’s disease therapy ...

But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.

MRI has shown that increases in the white matter of the brain and ventricle volume may be risk factors for the progression of ...

In JAMA Neurology, the group challenged the "movement" to define Alzheimer's disease as a "purely biological entity based on biomarker findings." ...

Dr. Schacterle is a highly regarded leader who has successfully led global regulatory and quality activities across multiple neurologic and psychiatric therapeutic areas and all stages of development, ...

is recommending the diagnosis of AD be limited to individuals with mild cognitive impairment or dementia and not be applied ...